FATE - Fate Therapeutics' NK cell candidate shows clinical response in early-stage lymphoma study

Fate Therapeutics (FATE) rises 7% after hours, after announcing interim data from dose escalation Phase 1 study evaluating FT516 in combination with rituximab (Roche's Rituxan)for relapsed/ refractory B-cell lymphoma.FT516 is an off-the-shelf NK cell product candidate engineered to express a high affinity to a receptor called CD16 Fc.Three of four heavily treated patients achieved objective response, including two complete responses.In one patient whose interim tumor assessment showed a partial response after the first FT516 treatment cycle, the response deepened to complete response after second FT516 treatment cycle, suggesting that additional FT516 treatment cycles can confer clinical benefit.Dose escalation is continuing in the current dose cohort of 300 million cells per dose in combination with rituximab, and a fourth dose cohort of 900 million cells per dose in combination with rituximab is planned.On the safety front, no dose-limiting toxicities, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or graft-versus-host disease, were observed.

For further details see:

Fate Therapeutics' NK cell candidate shows clinical response in early-stage lymphoma study